| 李 姗,邓小容,谭 杰,方厚盈,余修贤.阿托伐他汀强化降脂治疗急性脑梗死的疗效及对TNF-α、IL-10、IL-18、MMP-9水平的影响[J].,2018,(11):2141-2144 |
| 阿托伐他汀强化降脂治疗急性脑梗死的疗效及对TNF-α、IL-10、IL-18、MMP-9水平的影响 |
| Effect of Atorvastatin Intensive Lipid-Lowering Therapy on Acute Cerebral Infarction and its Effect on Levels of TNF-α, IL-10, IL-18, MMP-9 |
| 投稿时间：2017-10-31 修订日期：2017-11-24 |
| DOI：10.13241/j.cnki.pmb.2018.11.030 |
| 中文关键词: 急性脑梗死 阿托伐他汀 强化降脂 临床疗效 炎症因子 基质金属蛋白酶 |
| 英文关键词: Acute cerebral infarction Atorvastatin Intensive lipid-lowering Clinical efficacy Inflammatory factor Matrix metalloproteinase |
| 基金项目:湖北省自然科学基金项目（2012CDB06802） |
|
| 摘要点击次数: 548 |
| 全文下载次数: 251 |
| 中文摘要: |
| 摘要 目的：探讨阿托伐他汀强化降脂治疗急性脑梗死（ACI）的临床疗效，并分析其对肿瘤坏死因子-α（TNF-α）、白细胞介素-10（IL-10）、白细胞介素-18（IL-18）及基质金属蛋白酶-9（MMP-9）水平的影响。方法：选取2015年3月-2016年12月我院收治的82例ACI患者，采用随机数字表法随机分为强化组（n=41）与常规组（n=41）。在常规治疗的基础上，常规组患者给予20 mg/次的阿托伐他汀治疗，强化组患者给予40 mg/次的阿托伐他汀治疗，两组均连续治疗8w。治疗结束后对比两组患者的临床疗效，对比两组患者治疗前后总胆固醇（TC）、三酰甘油（TG）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）、组织型纤溶酶原激活物（t-PA）、血浆纤溶酶原激活物抑制剂-1（PAI-1）、血浆纤维蛋白原（FIB）、TNF-α、IL-10、IL-18、MMP-9水平。结果：强化组与常规组患者的总有效率分别为95.12%、80.49%，与常规组对比，强化组患者的临床总有效率明显升高（P<0.05）；两组患者治疗后的TC、TG、LDL-C、PAI-1、FIB、TNF-α、IL-18、MMP-9水平均较治疗前显著降低，HDL-C、t-PA、IL-10水平均显著升高（P<0.05），且治疗后强化组患者的TC、TG、LDL-C、PAI-1、FIB、TNF-α、IL-18、MMP-9水平均低于常规组，HDL-C、t-PA、IL-10均高于常规组（P<0.05）。结论：阿托伐他汀强化降脂治疗ACI疗效较好，能够显著改善患者血脂、纤溶系统及炎症因子相关指标水平，具有降脂、调节纤溶活性及抑制炎症的作用。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the clinical efficacy of atorvastatin intensive lipid-lowering therapy on patients with acute cerebral infarction, and to analyze the effects on levels of tumor necrosis factor-α (TNF-α), interleukin-10 (IL-10), interleukin-18 (IL-18) and matrix metalloproteinase-9 (MMP). Methods: Selected 82 patients with ACI who were treated in our hospital from March 2015 to December 2016,and they were randomly divided intensive group (n=41) and conventional group (n=41). On the basis of conventional treatment, patients in the conventional group were treated with atorvastatin 20 mg/times, patients in intensive group were treated with atorvastatin 40 mg/times, and the two groups were treated with continuous 8w. Compared the clinical efficacy of two groups after treatment, and the levels of total cholesterol (TC), three glycerol (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), tissue type plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PAI-1), plasma fibrinogen (FIB), TNF-α, IL-10, IL-18, MMP-9 in two group before and after treatment. Results: The total effective rates of the intensive group and the conventional group were 95.12% and 80.49% respectively, compared with the conventional group, the total effective rate of the patients in the intensive group was significantly increased (P<0.05). The levels of TC, TG, LDL-C, PAI-1, FIB, TNF-α, IL-18, MMP-9 in the two groups after treatment were significantly lower than those before treatment, the levels of HDL-C, t-PA and IL-10 were increased significantly (P<0.05). After treatment, the levels of TC, TG, LDL-C, PAI-1, FIB, TNF-α, IL-18, MMP-9 in the intensive group were lower than those in the conventional group, and the levels of HDL-C, t-PA and IL-10 were higher than those of the conventional group (P<0.05). Conclusion: The curative effect of atorvastatin intensive lipid-lowering in treatment of ACI is better, and it can significantly improve the level of blood lipids, fibrinolytic system and inflammatory factors, which has the effects of lowering blood fat, regulating fibrinolytic activity and inhibiting inflammation. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
